Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response
- PMID: 12472183
- DOI: 10.1081/imm-120016244
Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response
Abstract
The present studies were carried out in order to investigate the cross-reaction of botulinum neurotoxins (BoNTs) with human and mouse antibodies against tetanus neurotoxin (TeNT) and determine whether injection of BoNT into a host that has been primed with TeNT would result in boosting of the response to the injected BoNT. Human antisera against TeNT obtained from 9 individuals were found to exhibit substantial cross-reaction with BoNTs A and B. We prepared antibodies (Abs) against inactivated tetanus neurotoxin (TeNT) in outbred mice and determined the binding of these Abs to active TeNT and active botulinum neurotoxins (BoNTs) A and B. Blood samples were collected before immunization (day 0) and on days 42, 82 and 125 after the first injection. The reactions of these sera with the immunizing antigen (inactivated TeNT), active TeNT, active BoNT/A and active BoNT/B were determined. At a fixed dilution (1:62.5 v/v), the sera contained high levels of Abs that reacted with TeNT and also with BoNTs A and B. Throughout the test period (up through day 125) and at different dilutions the cross-reactions of the antisera with BoNT/B were almost twice those with BoNT/A. The reactions of the antisera with the immunizing antigen (inactive TeNT) or with active TeNT were essentially equal throughout the dilution range tested (1:16-1:500 v/v). To determine whether injection of BoNT/A or B into a host that had been primed with TeNT resulted in boosting of the response to the priming antigen (TeNT) as well as BoNT/A or B, mice were primed with TeNT and boosted 21 days later with TeNT, BoNT/A or BoNT/B. Appropriate controls were also employed. Blood samples were collected prior to TeNT priming (day -1) and on days 21, 32, 46 and 67 after priming. In TeNT-primed mice, BoNTs A or B boosted the anti-TeNT Ab responses slightly but had no significant boosting effect on the Ab populations that bind to BoNTs A or B. It is concluded that while Abs against TeNT cross react with BoNTs and the cross reaction with BoNT/B is almost double that of BoNT/A, injection of BoNTs A or B in the presence of a prior active immunity against TeNT is not very likely to make the host mount an Ab response against the injected BoNT.
Similar articles
-
Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):268-73. doi: 10.2174/187153012802002893. Endocr Metab Immune Disord Drug Targets. 2012. PMID: 22385115
-
Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.Hum Vaccin Immunother. 2014;10(7):1874-9. doi: 10.4161/hv.28937. Hum Vaccin Immunother. 2014. PMID: 25424795 Free PMC article.
-
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.Immunobiology. 2012 Jan;217(1):17-27. doi: 10.1016/j.imbio.2011.08.009. Epub 2011 Aug 30. Immunobiology. 2012. PMID: 21962573
-
Basic immunological aspects of botulinum toxin therapy.Mov Disord. 2004 Mar;19 Suppl 8:S68-84. doi: 10.1002/mds.20020. Mov Disord. 2004. PMID: 15027058 Review.
-
Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.Crit Rev Immunol. 2010;30(2):167-87. doi: 10.1615/critrevimmunol.v30.i2.50. Crit Rev Immunol. 2010. PMID: 20370628 Review.
Cited by
-
Botulinum toxin for the management of bladder dysfunction.Drugs. 2006;66(10):1301-18. doi: 10.2165/00003495-200666100-00001. Drugs. 2006. PMID: 16903766 Review.
-
Botulinum toxin in clinical practice.J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7. doi: 10.1136/jnnp.2003.034702. J Neurol Neurosurg Psychiatry. 2004. PMID: 15201348 Free PMC article. Review.
-
Hapten mediated display and pairing of recombinant antibodies accelerates assay assembly for biothreat countermeasures.Sci Rep. 2012;2:807. doi: 10.1038/srep00807. Epub 2012 Nov 12. Sci Rep. 2012. PMID: 23150778 Free PMC article.
-
Emerging opportunities for serotypes of botulinum neurotoxins.Toxins (Basel). 2012 Nov 7;4(11):1196-222. doi: 10.3390/toxins4111196. Toxins (Basel). 2012. PMID: 23202312 Free PMC article. Review.
-
Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action.J Cutan Aesthet Surg. 2008 Jan;1(1):3-6. doi: 10.4103/0974-2077.41148. J Cutan Aesthet Surg. 2008. PMID: 20300330 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical